NKX2-2

Across TCGA pan-cancer cohorts, NKX2-2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NKX2-2 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher NKX2-2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NKX2-2 expression acts as an unfavorable survival marker.

HNSC, LUAD, and ESCA are the cancer types where NKX2-2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.223	0.752	<.001	57	view →
LUAD	OS	Median	III,IV	0.188	0.668	<.001	31	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NKX2-2–HNSC (OS)

Open the HNSC breakdown →